New York University-ko ikertzaileekin lankidetzan egindako argitalpenak (20)

2024

  1. Towards the personalization of septic shock resuscitation: The fundamentals of ANDROMEDA-SHOCK-2 trial

    Revista Espanola de Anestesiologia y Reanimacion, Vol. 71, Núm. 2, pp. 112-124

2020

  1. Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach

    Arthritis Care and Research, Vol. 72, Núm. 12, pp. 1800-1808

2019

  1. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus

    Annals of the Rheumatic Diseases, Vol. 78, Núm. 9, pp. 1151-1159

  2. Comparison of real world and core laboratory lupus anticoagulant results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) clinical database and repository

    Journal of Thrombosis and Haemostasis, Vol. 17, Núm. 12, pp. 2069-2080

2018

  1. Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study

    Arthritis Care and Research, Vol. 70, Núm. 10, pp. 1478-1487

2015

  1. Anti-C1q antibodies in systemic lupus erythematosus

    Lupus, Vol. 24, Núm. 1, pp. 42-49

  2. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer

    JAMA - Journal of the American Medical Association, Vol. 313, Núm. 13, pp. 1347-1361

  3. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013

    The Lancet, Vol. 385, Núm. 9963, pp. 117-171

  4. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013

    The Lancet, Vol. 386, Núm. 10010, pp. 2287-2323

  5. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: Quantifying the epidemiological transition

    The Lancet, Vol. 386, Núm. 10009, pp. 2145-2191

  6. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013

    The Lancet, Vol. 386, Núm. 9995, pp. 743-800

  7. Mood disorders in systemic lupus erythematosus: Results from an international inception cohort study

    Arthritis and Rheumatology, Vol. 67, Núm. 7, pp. 1837-1847

2013

  1. Cancer risk in systemic lupus: An updated international multi-centre cohort study

    Journal of Autoimmunity, Vol. 42, pp. 130-135

2012

  1. 2012 American college of rheumatology guidelines for management of gout. part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia

    Arthritis Care and Research, Vol. 64, Núm. 10, pp. 1431-1446

  2. 2012 American college of rheumatology guidelines for management of gout. part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis

    Arthritis Care and Research, Vol. 64, Núm. 10, pp. 1447-1461

  3. Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus

    Arthritis and Rheumatism, Vol. 64, Núm. 8, pp. 2677-2686

  4. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010

    The Lancet, Vol. 380, Núm. 9859, pp. 2197-2223

  5. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010

    The Lancet, Vol. 380, Núm. 9859, pp. 2163-2196

1988

  1. PLASMA HOMOVANILLIC-ACID AS A PREDICTOR OF RESPONSE TO NEUROLEPTICS

    ARCHIVES OF GENERAL PSYCHIATRY, Vol. 45, Núm. 6, pp. 564-567

1987

  1. ELEVATION OF PLASMA HOMOVANILLIC-ACID LEVEL CAN BE DETECTED WITHIN 4 HOURS AFTER INITIATION OF HALOPERIDOL TREATMENT

    ARCHIVES OF GENERAL PSYCHIATRY